510(k) device
TearCare MGX System
Sight Sciences, Inc. · Eyelid Thermal Pulsation System (ORZ, Class II) · First FDA decision Dec 27, 2023, newest Apr 27, 2026Dry eye
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
510(k) pathway
Device trials
1
Naming "TearCare MGX"
MAUDE reports
0
Brand "TearCare MGX", since 2015
PubMed studies
0
Mentioning "TearCare MGX"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing TearCare MGX System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- TearCare MGX System510(k)
K252409 · Decided Apr 27, 2026 · 269 days after receipt
Device type: Eyelid Thermal Pulsation System (ORZ) · Ophthalmology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "TearCare MGX", any status and sponsor, newest update first.
Sight Sciences, Inc.Not on our public-company list
NCT07365735 · 21 participants · Start Mar 17, 2026 · Primary completion May 19, 2026
Device: localized heat therapy · For: Meibomian Gland Dysfunction (Disorder)
Sites: Brecksville, Ohio
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "TearCare MGX", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code ORZ
35 reports: 5 malfunction, 29 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "TearCare MGX"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code ORZ.
- LipiFlow Thermal Pulsation SystemTearscience, Inc. · 510(k) 2019
- TearCare SystemSight Sciences, Inc. · 510(k) 2026
- Tixel i (TXLI0001)Novoxel , Ltd. · 510(k) 2024
- Systane iLux2Tear Film Innovations, Inc. · 510(k) 2020
- iLux Instrument, iLux DisposableTear Film Innovations, Inc. · 510(k) 2017
- Lipflow Thermal Pulsation System (Formerly Manual Mini System)Tearscience, Inc. · De Novo 2011
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.